How should pulmonary hypertension be diagnosed and managed?

Pulmonary Hypertension: Diagnosis and Management

Diagnostic Approach

Begin with echocardiography as your first-line diagnostic test when you suspect pulmonary hypertension based on symptoms like dyspnea, fatigue, chest pain, or signs of right heart failure 1. This stepwise algorithmic approach prioritizes identifying which patients need referral to specialized PH centers and invasive assessment.

Initial Screening and Risk Stratification

When echocardiography shows high or intermediate probability of PH (based on tricuspid regurgitation velocity and other echo parameters), immediately proceed with:

• ECG - look for right axis deviation, right ventricular hypertrophy, right atrial enlargement
• Chest radiograph - assess for enlarged pulmonary arteries, right heart enlargement
• Pulmonary function tests with DLCO - mandatory to identify Group 3 (lung disease) PH 1
• Arterial blood gases - evaluate for hypoxemia and hypercapnia
• High-resolution CT chest - should be considered in all PH patients 1
• Routine labs: complete blood count, comprehensive metabolic panel, thyroid function, HIV testing, immunology panel (ANA, anti-Scl-70) 1

Critical decision point: If echocardiography shows low probability of PH, stop the workup and consider alternative diagnoses 1.

Distinguishing PH Groups

After initial testing, systematically exclude the most common causes:

Group 2 (Left Heart Disease): If left ventricular dysfunction, valvular disease, or diastolic dysfunction is present, treat the underlying cardiac condition first. Only pursue further PH workup if signs of severe PH or right ventricular dysfunction persist despite optimal treatment 1.

Group 3 (Lung Disease): If significant parenchymal lung disease or obstructive/restrictive patterns on PFTs explain the symptoms, treat the underlying lung disease. Again, only continue PH evaluation if disproportionately severe PH or RV dysfunction exists 1.

Mandatory V/Q Scan

Ventilation/perfusion or perfusion lung scan is required in all patients with unexplained PH to exclude chronic thromboembolic pulmonary hypertension (CTEPH) 1. This is a Class I recommendation because CTEPH is potentially curable with surgery, and missing this diagnosis has devastating consequences.

• If mismatched perfusion defects are present → proceed to CT pulmonary angiography and right heart catheterization 1
• Pitfall: CT angiography alone may miss CTEPH diagnosis; V/Q scan is more sensitive 1

Definitive Diagnosis: Right Heart Catheterization

Right heart catheterization is essential for accurate diagnosis and must be performed before initiating PAH-specific therapy 1, 2. The updated hemodynamic definition (as of 2024) requires 3:

• Mean pulmonary artery pressure (mPAP) >20 mmHg (lowered from the previous 25 mmHg threshold)
• Pre-capillary PH: PAWP ≤15 mmHg AND PVR >2 Wood Units
• Post-capillary PH: PAWP >15 mmHg
  • Isolated post-capillary: PVR ≤2 WU
  • Combined pre- and post-capillary: PVR >2 WU

This threshold reduction aims to identify patients earlier in their disease course, as delayed diagnosis is linked to increased morbidity and mortality 4.

Additional Workup for PAH Subtypes

Once pre-capillary PH is confirmed:

• Abdominal ultrasound - screen for portal hypertension (portopulmonary hypertension) 1
• Detailed drug/toxin exposure history - mitomycin-C and carfilzomib now have "definite association" with PAH 3
• Connective tissue disease screening - if not already done
• Genetic testing - consider in idiopathic PAH, especially if family history or young age

Contraindication: Open or thoracoscopic lung biopsy is NOT recommended in PAH patients (Class III recommendation) 1.

Management Strategy

Immediate Referral Criteria

Refer to a specialized PH center immediately (fast-track referral) if 3:

• High probability of severe pulmonary vascular disease on initial workup
• Any signs of right heart failure
• Confirmed or suspected PAH (Group 1)
• Confirmed or suspected CTEPH (Group 4)

Treatment by PH Group

Group 4 (CTEPH): Surgical pulmonary endarterectomy is the treatment of choice for eligible patients and offers potential cure 2. For inoperable or persistent/recurrent CTEPH, riociguat (soluble guanylate cyclase stimulator) is the only licensed targeted therapy 2.

Group 1 (PAH): Requires PAH-specific therapies targeting three pathways 5:

1. Nitric oxide pathway: Phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators
2. Prostacyclin pathway: Prostacyclin analogues, prostacyclin receptor agonists
3. Endothelin pathway: Endothelin receptor antagonists

Risk stratification tools guide treatment intensity and combination therapy decisions 5. Lung transplantation remains the only curative option for PAH 5.

Groups 2 and 3: Management primarily involves treating the underlying left heart disease or lung disease 2. PAH-specific therapies are generally not indicated and may be harmful.

Common Pitfalls to Avoid

• Don't skip the V/Q scan - CT alone misses CTEPH cases 1
• Don't start PAH-specific therapy without RHC confirmation - hemodynamic confirmation is mandatory
• Don't delay referral - patients often present with advanced disease; early expert involvement improves outcomes 6
• Don't assume all PH is the same - treatment differs dramatically by group; misclassification leads to inappropriate therapy
• Be aware of access barriers - Medicaid patients, those with mental health diagnoses, and those living far from PH centers are significantly less likely to receive expert care 6

Exercise Pulmonary Hypertension

The 2024 definition includes exercise PH: normal mPAP at rest with abnormal increase during exercise, defined as mPAP/cardiac output slope >3 mmHg/L/min 3. This may be relevant for symptomatic patients with normal resting hemodynamics, though clinical implications are still being defined.